{"id":667042,"date":"2023-09-09T12:26:01","date_gmt":"2023-09-09T12:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667042"},"modified":"2023-09-09T12:26:01","modified_gmt":"2023-09-09T12:26:01","slug":"underactive-bladder-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-astellas-pharma-europe-bv-taiho-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/underactive-bladder-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-astellas-pharma-europe-bv-taiho-pharma_667042.html","title":{"rendered":"Underactive Bladder Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Astellas Pharma Europe B.V, Taiho Pharma"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1694176329.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Underactive Bladder Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Astellas Pharma Europe B.V, Taiho Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1694176329.jpeg\" alt=\"Underactive Bladder Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Astellas Pharma Europe B.V, Taiho Pharma\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cUnderactive Bladder Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s<strong> &ldquo;Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Underactive Bladder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/underactive-bladder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Underactive Bladder Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Underactive Bladder Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Underactive Bladder market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>In 2021, there were<strong> 41,648,187<\/strong> moderate to severe LUTS cases reported in EU4 and the UK; this number is projected to rise from 2022 to 2032<\/li>\n<li>In EU4 and the UK, there were <strong>892,604 diagnosed prevalent cases<\/strong> of Underactive Bladder in 2021, and this number is projected to climb at a respectable CAGR from 2019 to 2032<\/li>\n<li>Germany had the greatest diagnosed prevalent population of UAB among the European nations in 2021, with roughly <strong>256,256 cases<\/strong>. Italy was next, with 194,334 diagnosed prevalent cases. However, with <strong>119,307 cases<\/strong>, France had the fewest diagnosed cases of the widespread disease<\/li>\n<li>In 2021, Japan had <strong>184,492 diagnosed cases<\/strong> of UAB, and by the end of 2032, that number is expected to increase<\/li>\n<li><strong>Key Underactive Bladder Companies:<\/strong> Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others<\/li>\n<li><strong>Key Underactive Bladder Therapies:<\/strong> ASP8302, TAC-302, and others<\/li>\n<li>The Underactive Bladder epidemiology based on gender analyzed that males predominantly has the higher number of diagnosed prevalent cases than females<\/li>\n<li>The Underactive Bladder market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Underactive Bladder pipeline products will significantly revolutionize the Underactive Bladder market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Underactive Bladder Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">An underactive bladder (UAB) (usually referred to as detrusor underactivity) is a bladder that has a contraction that is weaker and\/or shorter in duration, causing prolonged or delayed bladder emptying or the inability to completely empty the bladder within a typical time frame.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Underactive Bladder Market Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/underactive-bladder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/underactive-bladder-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Underactive Bladder Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Underactive Bladder Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Underactive Bladder market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Underactive Bladder<\/li>\n<li>Prevalent Cases of Underactive Bladder by severity<\/li>\n<li>Gender-specific Prevalence of Underactive Bladder<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Underactive Bladder<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Underactive Bladder epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/underactive-bladder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Underactive Bladder Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Underactive Bladder Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Underactive Bladder market or expected to get launched during the study period. The analysis covers Underactive Bladder market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Underactive Bladder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Underactive Bladder Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ASP8302:<\/strong> Astellas Pharma Europe B.V<\/li>\n<li><strong>TAC-302:<\/strong> Taiho Pharmaceutical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Underactive Bladder market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/underactive-bladder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Underactive Bladder Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Underactive Bladder Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The existing treatment paradigm consists mainly of off-label drugs. The untapped market for branded drugs presents lucrative avenues for market growth<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Underactive Bladder Market Opportunities<\/p>\n<ul style=\"text-align: justify;\">\n<li>There is room for branded therapeutic modalities with good safety and efficacy data along with progressive clinical trials<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Underactive Bladder Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Underactive Bladder Companies:<\/strong> Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others<\/li>\n<li><strong>Key Underactive Bladder Therapies:<\/strong> ASP8302, TAC-302, and others<\/li>\n<li><strong>Underactive Bladder Therapeutic Assessment:<\/strong> Underactive Bladder current marketed and Underactive Bladder emerging therapies<\/li>\n<li><strong>Underactive Bladder Market Dynamics:<\/strong> Underactive Bladder market drivers and Underactive Bladder market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Underactive Bladder Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Underactive Bladder Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Underactive Bladder companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/underactive-bladder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Underactive Bladder Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Underactive Bladder Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Underactive Bladder<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Underactive Bladder<\/p>\n<p style=\"text-align: justify;\">4. Underactive Bladder Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Underactive Bladder Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Underactive Bladder Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Underactive Bladder Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Underactive Bladder&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Underactive Bladder Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Underactive Bladder Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Underactive Bladder Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Underactive Bladder Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Underactive Bladder Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Underactive Bladder Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Underactive Bladder Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Underactive Bladder Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Underactive Bladder Appendix<\/p>\n<p style=\"text-align: justify;\">18. Underactive Bladder Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=underactive-bladder-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-astellas-pharma-europe-bv-taiho-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=underactive-bladder-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-astellas-pharma-europe-bv-taiho-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cUnderactive Bladder Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the DelveInsight&rsquo;s &ldquo;Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2032&Prime; &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/underactive-bladder-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-astellas-pharma-europe-bv-taiho-pharma_667042.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,439,417,406,423],"tags":[],"class_list":["post-667042","post","type-post","status-publish","format-standard","hentry","category-Business","category-Leisure-Activities","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=667042"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667042\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=667042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=667042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=667042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}